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Abstract
Summary We evaluated the influence of baseline age, bone
mineral density (BMD), and serum levels of vitamin D on the
response to risedronate treatment. Risedronate consistently
increased BMD, but our results suggest vitamin D supplemen-
tation may be necessary to achieve optimal treatment effect.
Furthermore, early intervention may help prevent bone
fractures.
Introduction We aimed to investigate the influence of baseline
age, BMD, and vitamin D insufficiency on the response to
risedronate treatment.
Methods Data regarding 1447 patients was obtained from the
registries of three phase III clinical trials of risedronate. The
response to treatment was expressed in terms of BMD in-
crease and occurrence of new vertebral fractures. The patients
were stratified by baseline values for age (<65, 65–72, and
≥72 years), lumbar spine BMD T-score (osteoporotic, <−2.5;
and non-osteoporotic, ≥− 2.5), and serum levels of 25-
hydroxyvitamin D (deficient, <21 ng/mL; and non-deficient,
≥21 ng/mL).
Results Risedronate consistently increased lumbar spine
BMD in all the groups, with similar percentage and absolute
increments in all the age tertiles. The percentage, but not ab-
solute, increment in BMD was significantly higher
(p = 0.0003) in the osteoporotic than that in the non-
osteoporotic patients (baseline). Of the 1330 patients whose
baseline serum levels of 25-hydroxyvitamin D were available,
44.7% had vitamin D deficiency (<20 ng/mL), while 89.2%
had insufficiency (<30 ng/mL). The percentage and absolute
increments in BMDwere lower (p < 0.05 and p < 0.01, respec-
tively) in the vitamin D-deficient than those in the non-
deficient patients. New vertebral fractures occurred in 1.5
and 0.8% of the osteoporotic and non-osteoporotic patients,
respectively (end of the treatment).
Conclusions Therapeutic response in elderly patients is con-
sistent, but early initiation of risedronate treatment may help
prevent fractures. Risedronate-induced increase in BMD is
lower in patients with vitamin D deficiency, suggesting that
vitamin D supplementation is important to achieve optimal
treatment response.
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Introduction
Bisphosphonates are widely used to treat osteoporosis, and the
treatment is effective in most osteoporosis patients, although
there are some patients known as Bnon-responders^ [1, 2].
Previous reports have indicated that factors involved in insuf-
ficient response include secondary osteoporosis [2–6], ad-
vanced age [7, 8], vitamin D deficiency [2, 4–6, 9–12], and
poor compliance [2–5].
While some studies [7, 8, 13] have examined the relation-
ship between age and fracture reduction in the context of
risedronate treatment, there is little information on whether
* T. Mawatari
mawtaro@gmail.com
1 Department of Orthopaedic Surgery, Hamanomachi Hospital,
Fukuoka, Japan
2 Department of Orthopaedic Surgery, Graduate School of Medical
Sciences, Kyushu University, Fukuoka, Japan
3 Data Science Group, Clinical Development Department, EA Pharma
Co., Ltd., Tokyo, Japan
4 Department of Orthopaedic Surgery, Kyushu Rosai Hospital,
Fukuoka, Japan
Osteoporos Int (2017) 28:1279–1286
DOI 10.1007/s00198-016-3848-4
risedronate-induced increase in bone mineral density (BMD)
is consistent in elderly patients.
Furthermore, while it was shown that the percentage in-
crease in BMD is related to the baseline BMD [14], absolute
increments in BMD have not been described. Finally, al-
though it was shown that vitamin D levels are correlated with
the response to treatment for postmenopausal osteoporosis in
terms of BMD changes and fracture rates [15], this relation-
ship has not been fully described.
Risedronate is a third-generation bisphosphonate contain-
ing a pyridinyl group. Risedronate has already been shown to
benefit postmenopausal women with established osteoporosis
[13, 16–21]. Similar efficacy has been reported in Japanese
clinical trials for oral administration of daily, weekly, or
monthly single doses (2.5, 17.5, and 75 mg, respectively)
[19, 20, 22, 23]. Risedronate was approved for use in clinical
practice in Japan following a series of phase III trials during
which vitamin D was not supplemented in order to ensure
consistency with previous trials [24]. Therefore, by analyzing
the data collected during these trials, it is possible to explore
the influence of vitamin D insufficiency and deficiency on the
response to risedronate treatment.
The aim of the present study was to investigate the rela-
tionship between baseline characteristics (age, BMD, and se-
rum levels of vitamin D) and therapeutic effects (change in
BMD and incidence of new vertebral fractures) of risedronate
treatment for osteoporosis by analyzing data from three phase
III clinical trials in Japanese populations.
Methods
Study design
The present study analyzed combined data from three ran-
domized, double-blind, clinical phase III trials for risedronate,
namely CCT-003 [19], CCT-101 [22], and CCT-301 [23].
These trials were carried out as multicenter studies in Japan
between March 1999 and August 2011. The primary efficacy
endpoint was the percent change in mean lumbar spine
BMD (LS-BMD), and the results were similar between
CCT-003 and CCT-101, and between CCT-003 and CCT-
301 [19, 22, 23].
Trial CCT-003 consisted of 48 weeks of treatment, where-
by eligible patients were randomly assigned to receive either a
daily oral dose of risedronate (2.5 mg) or an intermittent cy-
clical dosage regimen of etidronate (each cycle consisted of a
2-week period of treatment with 200 mg/day and a 10-week
medication-free period). Trial CCT-101 also consisted of
48 weeks of treatment, but eligible patients were randomly
assigned to receive either a weekly (17.5 mg) or a daily
(2.5 mg) oral dose of risedronate. Finally, trial CCT-301
consisted of 12 months of treatment, whereby eligible patients
were randomly assigned to receive either a monthly (75 mg)
or a daily (2.5 mg) oral dose of risedronate. In all the trials,
blinding to the study drug was maintained by a double-
dummy technique using active drugs and corresponding pla-
cebo tablets.
All the patients were treated in an ambulatory regime and
supplemented with calcium lactate (1.54 g/day, corresponding
to 200 mg of calcium per day) throughout the study period.
However, vitamin D was not supplemented in order to ensure
consistency with previous clinical trials [24]. Throughout the
study period, concomitant use of any drugs known to affect
bone metabolism was prohibited. The study protocols were
approved by the Institutional Review Board of each institution
prior to initiation of the study, and all the patients gave written
informed consent before registration. The trials were conduct-
ed according to the Good Clinical Practice guidelines and in
accordance with the Helsinki declaration. Details of the study
design, patients involved, and protocols of these trials have
been described elsewhere [19, 22, 23].
Selection of patients
The present study consists of a post-hoc analysis of data from
1447 osteoporosis patients who received treatment with
risedronate within one of the risedronate trials described
above. Ambulatory patients of either sex, aged 40–75 years
(trial CCT-003) or ≥50 years (trials CCT-101 and CCT-301),
with involutional osteoporosis were eligible if they met the
diagnostic criteria for primary osteoporosis established by
the Japanese Society for Bone and Mineral Research
(JSBMR) [25, 26]. Exclusion criteria included the following:
secondary osteoporosis or other diseases known to cause re-
duced bone mass; radiographic findings that might affect the
LS-BMD; recent use of drugs known to affect bone metabo-
lism; gastrointestinal diseases; hypocalcemia; hypercalcemia;
serious renal, hepatic, or cardiac diseases; malignant tumors
under treatment with antitumor agents; drug hypersensitivity;
and history of radiotherapy to the lumbar spine or pelvis
(Fig. 1).
Clinical examinations
The effect of risedronate treatment was evaluated in terms of
LS-BMD and the incidence of new, non-traumatic vertebral
fractures (including worsening of pre-existing fractures)
throughout the duration of treatment.
The LS-BMD (L2–L4) was determined at baseline and at
designated time points via dual-energy X-ray absorptiometry,
using QDR type instruments (trial CCT 301) or QDR type,
XR type, or DPX type instruments (trials CCT-003 and CCT-
101). These LS-BMD results were assessed by a specialized
central review committee blinded to patient information.
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Chest and lumbar spine X-rays were taken at baseline and
at the end of the trial. A specialized central review committee
decided whether there were pre-existing and new fractures, or
if worsening of pre-existing fractures occurred. Vertebral frac-
tures were judged based on the JSBMR diagnostic criteria for
primary osteoporosis [25, 26]. An incident vertebral fracture
was considered to have occurred if: the ratio of the central to
anterior vertebral height (C/A) was <0.8; the ratio of central to
posterior vertebral body height (C/P) was <0.8; the ratio of
anterior to posterior vertebral height (A/P) was <0.75; or A, C,
or P decreased by at least 20% from their baseline values. In
trials CCT-003 and CCT-101, a pre-existing vertebral fracture
was considered to have worsened if C/A, C/P, or A/P de-
creased by 20% or more from their baseline values [27]. In
trial CCT-301, a semi quantitative assessment method was
used to detect worsening of an existing fracture based on
whether A, C, or P had decreased by at least 20% (or 4 mm)
from their baseline values, in which case the condition was
labeled to have progressed by one grade or more [28]. In
addition, serum levels of 25-hydroxyvitamin D (further re-
ferred to as vitamin D) were measured at baseline by the
radioimmunoassay method.
Statistical analyses
In order to examine the influence of baseline characteristics
including age and BMD, the patients were stratified in groups
according to age tertiles at baseline (<65, 65–72, and
≥72 years) and to LS-BMD T-score at baseline (osteoporotic,
<−2.5; non-osteoporotic, ≥−2.5). To determine the most ap-
propriate cutoff level of serum levels of vitamin D relevant for
achieving optimal increase in BMD in response to risedronate
treatment, the Akaike’s information criterion (AIC) was
employed [29]. A smaller AIC value indicated a more reliable
model for predicting the outcome, and the serum levels of
vitamin D for the smallest AIC value were used as the cutoff.
One-way ANOVAwas used for comparing the percentage
and absolute increments in LS-BMD between patient groups
defined according to age. Two-tailed Student’s t tests were
conducted comparing the percentage and absolute changes
in LS-BMD between the two groups defined based on base-
line LS-BMD T-score. Chi-square tests were conducted for
comparing the incidence of new vertebral fractures between
the patient groups defined based on endpoint LS-BMD T-
score. All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
Out of the 1466 randomized patients (118 from the CCT-003
trial, 496 from the CCT-101 trial, and 852 from the CCT-301
trial), we assessed 1447 patients whose LS-BMDwas measured
at baseline (Fig. 1). The baseline characteristics of all the patients
included in our analysis are shown in Table 1. X-ray examina-
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Fig. 1 Patient inclusion flow
chart. Data were collected from
three randomized, double-blind,
clinical phase III trials for
risedronate (CCT-003, CCT-101,
and CCT-301). BMD bone
mineral density
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patients for whom X-ray examinations were available. Baseline
serum levels of vitamin D were <20 ng/mL for 595 patients
(44.7%), and <30 ng/mL for 1187 patients (89.2%), out of the
1330 patients for whom these data were available (Fig. 2).
Following treatment with risedronate, LS-BMD increased
significantly compared to baseline (5.62 ± 4.33%,
p < 0.0001). There were no statistically significant differences
among the age groups in terms of percentage (p = 0.1720) or
absolute (g/cm2) increments (p = 0.3524) in LS-BMD
(<65 years, n = 487, 5.40 ± 4.44%, 0.0350 ± 0.0284 g/cm2;
65–72 years, n = 489, 5.91 ± 4.20%, 0.0374 ± 0.0264 g/cm2;
≥72 years, n = 393, 5.54 ± 4.33%, 0.0354 ± 0.0272 g/cm2)
(Fig. 3a, b). Results were similar when the patients were strat-
ified into age groups using different cutoffs (<75, 75–80, and
≥80 years) rather than into tertiles (data not shown).
The percentage increment in LS-BMD was a significantly
higher (p = 0.0003) in the osteoporotic than that in the non-
osteoporotic patients (respectively: n= 1171, 5.80 ± 4.37%; n=
198, 4.59 ± 3.93%), while no significant difference (p= 0.7524)
was observed regarding the absolute BMD increments (0.0361 ±
0.0267 and 0.0354 ± 0.0308 g/cm2, respectively) (Fig. 3c, d).
The cutoff for serum levels of vitamin D was calculated as
21 ng/mL, according to the AIC. For the patients with baseline
serum levels of vitamin D of ≥21 ng/mL, both percentage and
absolute (g/cm2) increments of LS-BMD were significantly
higher (p= 0.0138 and p = 0.0078, respectively) than those in
the patients with baseline serum levels of vitamin D of <21 ng/
mL (respectively: n = 626, 5.99 ± 4.17%, 0.0383 ± 0.0264 g/
cm2; n = 635, 5.39 ± 4.42%, 0.0343 ± 0.0277 g/cm2) (Fig. 3e, f).
There was no statistically significant difference between
the patients with endpoint LS-BMD T-score <−2.5 (n = 871,
13 cases, 1.5%) and those with endpoint LS-BMD T-score
≥−2.5 (n = 481, 4 cases, 0.8%) regarding the incidence of
new vertebral fractures, but there was a trend for lower inci-
dence in the group with higher BMD (Fig. 4). A similar trend
was observed for the patients with baseline LS-BMD T-score
<−2.5 (n = 1159), as those with endpoint LS-BMD T-score <
−2.5 had a relatively lower incidence of new fracture (n = 869,
13 cases, 1.5%) than did the patients with endpoint LS-BMD
T-score ≥−2.5 (n = 290, 2 cases, 0.7%) (Fig. 5); this difference
did not reach statistical significance either.
Discussion
In our post-hoc analysis of data from a large-scale, strictly
controlled, phase III clinical trial conducted in Japan, we found
that risedronate consistently increased LS-BMD regardless of
the baseline age, BMD, or vitamin D deficiency. The influence
of such factors on the efficacy of osteoporotic treatment has
been previously studied, with conflicting conclusions.
Specifically, the study by McClung et al. [16] included 5445
osteoporotic women aged 70–79 years and 3886 women aged
≥80 years. The study participants, each of whom had at least one
clinical risk factor for hip fracture, received treatment with oral
risedronate or placebo for 3 years. It was found that BMD re-
sponse in the older patients was similar to that observed in the
younger cohort, and the effect on hip fracture risk was apparent
in the older patientswhose baseline BMDwasmeasured andwas
consistent with osteoporosis. Boonen et al. [7] also reported that
risedronate consistently reduced the risk for vertebral fracture
both in subjects younger than 80 years (hazard ratio, 0.61;
p < 0.001) and in those aged 80 years or older (hazard ratio,
0.56; p = 0.003); nevertheless, the reduction in risk for
nonvertebral fractures was statistically significant only in patients
younger than 80 years, and no treatment effect was seen in pa-
tients aged 80 years or older. The authors speculated that the
reduced treatment effect in terms of risk for nonvertebral
Table 1 Baseline characteristics for patients undergoing treatment with
risedronate for osteoporosis (n = 1447)
Characteristic Value
Age (years) 67.5 ± 7.2
Height (cm) 150.8 ± 6.0
Weight (kg) 49.4 ± 7.0
BMI (kg/m2) 21.8 ± 2.9
Sex (male/female) 31/1416
Use of risedronate (daily/weekly/monthly) 783/242/422
Lumbar spine BMD (g/cm2) 0.652 ± 0.075
T-Score −3.03 ± 0.65
Serum 25(OH)D levels (ng/mL) 20.9 ± 6.6a
Prevalent vertebral fractures (yes/no) 335/1071b
Data given as mean ± standard deviation, or number of subjects
BMI body mass index, BMD bone mineral density
a Data available for 1330 subjects
b Data available for 1406 subjects
Fig. 2 Distribution of baseline serum levels of 25-hydroxyvitamin D
(n = 1330). A significant number of patients had vitamin D deficiency
(<20 ng/mL) or insufficiency (<30 ng/mL)
1282 Osteoporos Int (2017) 28:1279–1286
fractures in the patients aged 80 years or older may reflect the
age-related increase of the influence of nonskeletal risk factors
(e.g., falling) for these types of fractures. Adami et al. [8] con-
ducted a longitudinal study regarding the incidence of inadequate
treatment response in osteoporosis patients, and concluded that
those with inadequate clinical response to treatment with
antiresorptive agents (alendronate, risedronate, and raloxifene)
were significantly older (p = 0.032) and more frequently had
multiple vertebral deformities (p = 0.013). Watts et al. [13] col-
lected data on 3684 postmenopausal women involved in the
Vertebral Efficacywith Risedronate Therapy trial. It was reported
that the incidence of new fractures decreased to a similar extent in
patients treated with risedronate and in those treated with place-
bos, and the effect was observed both in patients aged <70 years
and in those aged ≥70 years.With respect to alendronate therapy,
Ensrud et al. [30] performed post-hoc analyses of data from the
Fracture Intervention trial, and reported that the alendronate-
induced reduction in risk for fractures was similar for patients
aged <75 years and for those aged ≥75 years. Hochberg et al.
[31] analyzed data on 3658 postmenopausal women with
Fig. 3 Relationship between baseline characteristics and the increase in
LS-BMD. Patients were divided into age tertiles based on the age at
baseline. Percentage (a) and absolute (b) increments in LS-BMD from
baseline are shown. The patients were stratified into two cohorts by LS-
BMD (given by T-score) at baseline. Percentage (c) and absolute (d)
increments in LS-BMD are shown. The patients were stratified into two
cohorts by serum levels of 25-hydroxyvitamin D at baseline. Percentage
(e) and absolute (f) BMD increments in LS-BMD from baseline are
shown. Error bars represent standard deviation
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osteoporosis enrolled in the same Fracture Intervention trial, and
showed that alendronate is effective in reducing the risk of symp-
tomatic osteoporotic fractures across a spectrum of ages (55–
80 years). In our study on the effect of risedronate therapy, both
percentage increments and absolute increments in LS-BMD
were similar across the age tertiles, which is in agreement with
the previous reports on the effect of alendronate therapy [30, 31].
Regarding the influence of baseline BMD, Gordon et al.
[14] performed a linear regression analysis of the relationship
between baseline BMD and BMD percentage increase in the
lumbar spine and femoral neck, and found a statistically sig-
nificant negative correlation; however, the sample size in their
study was modest (n = 44), and absolute BMD increments
were not described. Ensrud et al. [30] also examined the con-
sistency of the effect of alendronate in preventing fractures
within groups of patients defined according to baseline BMD
of the femoral neck (FN-BMD); with respect to reducing the
risk of new vertebral fractures, the treatment appeared to be as
effective in women with FN-BMD <0.59 g/cm2 as in those
with FN-BMD ≥0.59 g/cm2. The authors concluded that
alendronate effectively reduces fracture risk in postmenopausal
women with vertebral fracture and low BMD, and the effect is
stronger in women at highest risk because of advanced age or
severe osteoporosis. Our results have shown that BMD per-
centage increments are 1.21% higher in the subjects who were
osteoporotic at baseline (T-score <−2.5) than those in the non-
osteoporotic subjects, while absolute increments did not differ.
On the other hand, as shown in Figs. 4 and 5, the incidence of
new vertebral fractures seems dependent on the endpoint
BMD, suggesting that risedronate therapy consistently in-
creases the absolute value of LS-BMD, but early intervention
may be important to ensure optimal reduction in fracture risk.
Vitamin D plays an essential role in the maintenance of
bone strength and muscle function. Vitamin D repletion is
pre-requisite inclusion criteria, and vitamin D is usually sup-
plemented in most of the current clinical trials of osteoporosis
treatments, though that is not always the case in routine clin-
ical practice. Therefore, the role of vitamin D in bisphospho-
nate therapy is an important clinical question. Adami et al. [15]
studied data on 1515 women with postmenopausal osteoporo-
sis undergoing treatment with antiresorptive agents including
alendronate, risedronate, and raloxifene for over 13 months;
they reported that vitamin D-deficient and -repleted subjects
differed significantly with respect to annual changes in spine
and hip BMD; the adjusted odds ratio measuring the risk for
incident fractures in vitamin D-deficient women relative to
that in vitamin D-repleted women was 1.77 (95% confidence
interval, 1.20–2.59; p = 0.004). In our present study, 595 out of
the 1330 patients (44.7%) had serum levels of vitamin D
<20 ng/mL, while 1187 out of the 1330 patients (89.2%) had
serum levels of vitamin D <30 ng/mL (Fig. 2). According to
the guidelines of the American Society of Endocrinology [32],
vitamin D deficiency and insufficiency are defined when the
serum levels of vitamin D are <20 and 21–29 ng/mL, respec-
tively, suggesting that 90% of the patients in our cohort had
vitamin D deficiency or insufficiency. These results are almost
consistent with those of Ishijima et al., who reported that vita-
min D levels were <30 ng/mL in 82% of Japanese postmeno-
pausal osteoporosis patients (n = 52) undergoing a 6-month
trial of alendronate therapy [33]. Okazaki et al. reported even
higher percentage of vitamin D deficiency: <20 ng/mL in
75.7% of the Japanese population [34].
On the other hand, Peris et al. reported that 30% of Spanish
postmenopausal osteoporotic women (n = 120) receiving
alendronate or risedronate showed inadequate response to
treatment, with significantly lower levels of vitamin D (22.4
± 1.3 vs. 26.6 ± 0.3 ng/mL, p = 0.01) and higher incidence of
vitamin D levels <30 ng/mL (91 vs. 69%, p = 0.019). Patients
with values of vitamin D >30 ng/mL had a greater increase in
LS-BMD than patients with values of vitamin D <30 ng/mL
(3.6 vs. 0.8%, p < 0.05) [10].
Fig. 5 Relationship between endpoint BMD and the incidence of new
vertebral fractures for patients with baseline BMD <−2.5
Fig. 4 Relationship between endpoint BMD and the incidence of new
vertebral fractures
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Ishijima et al. administered alendronate to 52 Japanese
postmenopausal women for 6 months; serum levels of vitamin
D of ≥25 ng/mL were determined to be the minimum levels
necessary to achieve an adequate effect of alendronate treat-
ment. The increase in LS-BMD after a 6-month alendronate
treatment was significantly lower in patients with serum vita-
min D levels <25 ng/mL (3.3%; 95% confidence interval, 1.7–
5.0%) than in those with serum vitamin D levels ≥25 ng/mL
(6.8%; 95% confidence interval, 3.8–9.4%) [33].
In accordance with those reports, both of the percent and
absolute increments in LS-BMD after risedronate treatment
were significantly higher for patients with serum levels of
vitamin D ≥21 ng/mL when compared to the those seen in
patients with serum levels of vitamin D <21 ng/mL (respec-
tively; 5.99 ± 4.17%, 0.0383 ± 0.0264 g/cm2; and 5.39 ±
4.42%, 0.0343 ± 0.0277 g/cm2; respectively, p = 0.0138 and
p = 0.0079), suggesting the importance of vitamin D repletion
in osteoporosis treatment.
The current study is limited by its post-hoc design. Another
limitation of this study is that no placebo groups were avail-
able for comparison in the trials considered, and therefore, the
effectiveness of risedronate on reducing fracture risk could not
be compared between younger and older patients.
Furthermore, other confounding factors remain to be investi-
gated. We believe that a further prospective study is necessary
to elucidate whether taking natural vitamin D supplements or
alfacalcidol is able to increase the therapeutic effects of
bisphosphonates against osteoporosis.
In conclusion, the results of this study suggest that
risedronate administration consistently increases the abso-
lute value of LS-BMD, regardless of age or baseline
BMD. However, early start of the treatment seems to be
important in order to prevent new fractures. Vitamin D
deficiency and insufficiency are common conditions, and
the BMD change in response to risedronate treatment
seems to be smaller in the patients with serum levels of
vitamin D <21 ng/mL when compared to the change seen
in the patients with serum levels of vitamin D ≥21 ng/mL.
This suggests that vitamin D supplementation may be im-
portant to achieve optimal LS-BMD response to
risedronate treatment.
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